Health
GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the Galleri® multi-cancer early detection (MCED) test performance and safety from its registrational PATHFINDER 2 study at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Oct. 17-21, 2025. The PATHFINDER 2 study, conducted under an FDA-approved investigational device exemption application, is the largest MCED interventional st
About this update from Grail, Inc.
[{"type":"text","content":"First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA) ","length":225,"tagName":"p","attribs":{}},{"type":"text","content":"Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highlight Galleri Performance in Symptomatic and Veteran Populations, Respectively","length":200,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., Sept. 23, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the Galleri® multi-cancer early detection (MCED) test performance and safety from its registrational PATHFINDER 2 study at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Oct. 17-21, 2025. The PATHFINDER 2 study, conducted under an FDA-approved investigational device exemption application, is the largest MCED interventional study conducted in the U.S. in an intended use population with no clinical suspicion of cancer.","length":659,"tagName":"p"},{"type":"image","alt":"GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)","displaySize":"","headline":null,"caption":"GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":76,"url":"https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LnMp0pobetiqZw3skecvAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf","width":400,"height":76}},"href":"https://mma.prnewswire.com/media/2460831/Grail_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"As previously reported, top-line results from evaluable PATHFINDER 2 study participants with 12 months of follow-up showed that adding the Galleri test to standard of care screening demonstrated substantially greater additional cancer detection, as well as a substantially ...